Urogen Pharma (NASDAQ:URGN) had its target price cut by Oppenheimer from $70.00 to $62.00 in a report published on Wednesday morning, The Fly reports.
A number of other research firms have also commented on URGN. Stifel Nicolaus set a $41.00 price target on shares of Urogen Pharma and gave the company a buy rating in a research report on Sunday, October 20th. Zacks Investment Research upgraded shares of Urogen Pharma from a sell rating to a hold rating in a research report on Saturday, October 26th. JPMorgan Chase & Co. reduced their price target on shares of Urogen Pharma from $40.00 to $39.00 and set a neutral rating on the stock in a research report on Wednesday. Cowen restated a buy rating on shares of Urogen Pharma in a research report on Monday. Finally, HC Wainwright set a $75.00 target price on shares of Urogen Pharma and gave the stock a buy rating in a research note on Monday, October 21st. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $51.86.
NASDAQ:URGN traded up $0.15 on Wednesday, reaching $26.30. The stock had a trading volume of 119,100 shares, compared to its average volume of 205,349. The company has a market capitalization of $506.13 million, a P/E ratio of -5.48 and a beta of 1.12. Urogen Pharma has a 1-year low of $20.72 and a 1-year high of $55.49. The stock has a fifty day moving average price of $23.01 and a 200-day moving average price of $31.67.
Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.26) by $0.20. As a group, equities analysts anticipate that Urogen Pharma will post -4.92 EPS for the current year.
In other Urogen Pharma news, CFO Peter P. Pfreundschuh sold 1,416 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $33.07, for a total value of $46,827.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 10.50% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Parallel Advisors LLC bought a new position in shares of Urogen Pharma in the third quarter worth about $36,000. Tower Research Capital LLC TRC raised its stake in shares of Urogen Pharma by 1,500.0% in the third quarter. Tower Research Capital LLC TRC now owns 2,000 shares of the company’s stock worth $47,000 after acquiring an additional 1,875 shares during the last quarter. Bank of Montreal Can bought a new position in shares of Urogen Pharma in the second quarter worth about $56,000. Signaturefd LLC bought a new position in shares of Urogen Pharma in the third quarter worth about $71,000. Finally, Nisa Investment Advisors LLC bought a new position in shares of Urogen Pharma in the third quarter worth about $100,000. 70.33% of the stock is owned by institutional investors.
Urogen Pharma Company Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Featured Story: Initial Public Offering (IPO)
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.